NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery.
about
Anti-HIV-1 nanotherapeutics: promises and challenges for the futureNanoscale drug delivery systems and the blood-brain barrierEvolving Drug Delivery Strategies to Overcome the Blood Brain Barrier.Cell delivery of therapeutic nanoparticlesDrug synergy of tenofovir and nanoparticle-based antiretrovirals for HIV prophylaxisDesign strategies and applications of circulating cell-mediated drug delivery systemsCellular Responses and Tissue Depots for Nanoformulated Antiretroviral TherapyProgress in antiretroviral drug delivery using nanotechnologyIn vitro suppression of oral squamous cell carcinoma growth by ultrasound-mediated delivery of curcumin microemulsionsPharmacokinetics, biodistribution, and toxicity of folic acid-coated antiretroviral nanoformulations.Brain dysfunction in the era of combination antiretroviral therapy: implications for the treatment of the aging population of HIV-infected individualsLong-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice.Macrophages offer a paradigm switch for CNS delivery of therapeutic proteins.Endosomal trafficking of nanoformulated antiretroviral therapy facilitates drug particle carriage and HIV clearance.Antiretroviral release from poly(DL-lactide-co-glycolide) nanoparticles in miceLong-acting antituberculous therapeutic nanoparticles target macrophage endosomes.Polyelectrolyte complex optimization for macrophage delivery of redox enzyme nanoparticles.Registered bioimaging of nanomaterials for diagnostic and therapeutic monitoring.Methods development for blood borne macrophage carriage of nanoformulated antiretroviral drugs.Cell-mediated drug delivery.Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages.Pharmacodynamics of long-acting folic acid-receptor targeted ritonavir-boosted atazanavir nanoformulations.Development of HIV reservoir targeted long acting nanoformulated antiretroviral therapiesOpposing regulation of endolysosomal pathways by long-acting nanoformulated antiretroviral therapy and HIV-1 in human macrophagesPulsed stable isotope labeling of amino acids in cell culture uncovers the dynamic interactions between HIV-1 and the monocyte-derived macrophage.Type and composition of surfactants mediating gene transfection of polyethylenimine-coated liposomes.Efficacy of Tat-conjugated ritonavir-loaded nanoparticles in reducing HIV-1 replication in monocyte-derived macrophages and cytocompatibility with macrophages and human neuronsProlonged-acting, multi-targeting gallium nanoparticles potently inhibit growth of both HIV and mycobacteria in co-infected human macrophages.Cell-mediated transfer of catalase nanoparticles from macrophages to brain endothelial, glial and neuronal cells.Compartmentalization, Viral Evolution, and Viral Latency of HIV in the CNS.Comparative manufacture and cell-based delivery of antiretroviral nanoformulations.Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells.Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics.Long-acting slow effective release antiretroviral therapy.Gallium nanoparticles facilitate phagosome maturation and inhibit growth of virulent Mycobacterium tuberculosis in macrophages.Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted mice.Functional proteome of macrophage carried nanoformulated antiretroviral therapy demonstrates enhanced particle carrying capacityDrug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment.Preclinical pharmacokinetics and tissue distribution of long-acting nanoformulated antiretroviral therapyMacrophage folate receptor-targeted antiretroviral therapy facilitates drug entry, retention, antiretroviral activities and biodistribution for reduction of human immunodeficiency virus infections
P2860
Q26828464-C5FC5586-07A8-41D1-90D4-AF874CC6FE4DQ27026978-1098B18F-9C00-48F9-8A27-96388F5CAC07Q28082016-5454E325-5353-4F19-9C3A-CC6680D90119Q28385606-E5C659AD-E8E6-45BC-8B26-448C25E2413BQ28486428-E98AAF28-157E-41E6-ADDA-3A28A093DE19Q28547179-C917D84B-6350-4414-9FC6-206F2E2E04D2Q28551873-3D5E45CD-ADFD-4E59-A458-78F50479C0BEQ30395011-9A93BDF7-6ACB-4D60-9A8F-A92829A809F1Q30469832-43BC3712-1E64-43D2-B475-3FDD92587B0CQ30603781-386CA6AC-FB78-4CC7-9341-0127A1C3D4A7Q33614467-1E009198-28FD-4020-B702-D088538834E9Q33625213-D72BA87F-CB3D-462A-A9A0-4F27C8E20787Q33631069-4F6A8541-ED71-4C99-91A3-D8144D22FE31Q34059457-830C4B81-9D64-4DA2-9743-3B21CA2F0F72Q34138487-D71C8F25-6F6A-4804-9547-FFCCB4F029ADQ34512904-A726D69C-8694-401E-B39A-010DB2E29E01Q34566992-507CBEA1-8FFD-4D78-A85A-BEDFBB5E51F8Q34639915-C7BE18DD-B824-4156-A58F-64CECB8F438AQ34639923-4F099306-895F-46B3-93F6-26FDAE965A48Q34709440-E3C5DCB8-F8E3-45A0-AFE5-FF6D7C32E67BQ34728884-DB45CA59-A9AE-4A32-B373-AA86D59A605DQ34745586-9914D18F-A76F-493F-9F81-ED42476DCAEDQ34797004-E035889E-BC5B-4C9F-A4DF-2E48F36EB97DQ35016131-DFECA74A-3F8F-4296-A91E-ED6E92D443DAQ35025824-23006BD8-CD2E-4AB8-B108-09C765F65B5AQ35071617-4BF32BDC-BD08-43DD-9550-CD4F938AD076Q35145361-68CE48F4-273D-475A-80D9-8A421EB59A2BQ35153311-8A093CC9-41A2-44EC-846A-BD5D35494C9FQ35194750-A3946736-B87E-4C65-8487-947BABFE1494Q35606068-95BA6B38-DEDA-41BA-A893-F2CE7C65691AQ35677168-013B8916-FCC8-45C2-B880-58B56649AD7EQ35979166-6FE37577-91EF-4653-B03C-8532DCA83781Q36107193-54190A56-3A90-48F8-9628-08035E6231E0Q36262152-60B1285E-79F5-458D-92A5-78A8D5388847Q36381046-4BA33724-76BA-409E-B6DA-413194A323C5Q36603756-203DFD33-5F64-4FBC-AA99-B2725DBB9221Q36875347-FF1ABA9D-A3D8-4CF5-AF6C-8692B30E9F92Q36934918-B54515A0-9DA9-47EC-8F0C-D3593598A700Q36969787-F99CBDDC-8D85-4AED-9A05-03715110DFE4Q37188867-29EFF943-E5AF-4503-8598-C5AD33A4D46D
P2860
NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
NanoART synthesis, characteriz ...... cyte-macrophage drug delivery.
@ast
NanoART synthesis, characteriz ...... cyte-macrophage drug delivery.
@en
type
label
NanoART synthesis, characteriz ...... cyte-macrophage drug delivery.
@ast
NanoART synthesis, characteriz ...... cyte-macrophage drug delivery.
@en
prefLabel
NanoART synthesis, characteriz ...... cyte-macrophage drug delivery.
@ast
NanoART synthesis, characteriz ...... cyte-macrophage drug delivery.
@en
P2093
P2860
P356
P1433
P1476
NanoART synthesis, characteriz ...... cyte-macrophage drug delivery.
@en
P2093
Ari S Nowacek
Barrett Rabinow
Georgette Kanmogne
Howard E Gendelman
Huanyu Dou
Jane Werling
Joellyn McMillan
Mahesh Chaubal
Michel Kanmogne
R Lee Mosley
P2860
P304
P356
10.2217/NNM.09.71
P577
2009-12-01T00:00:00Z